Jeffrey Varnes

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

Jeffrey W. Johannes, Amber Balazs, Derek Barratt et al. · Journal of Medicinal Chemistry · 2021 · 140 citations · Full text

Life Sciences, Medicinal Chemistry, Oncology +13

Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist

James S. Scott, Amber Balazs, Bernard Barlaam et al. · Journal of Medicinal Chemistry · 2020 · 111 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

Bernard Barlaam, Robert Casella, Justin Cidado et al. · Journal of Medicinal Chemistry · 2020 · 104 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

Srividya B. Balachander, Steven W. Criscione, Kate F. Byth et al. · Clinical Cancer Research · 2020 · 69 citations

Medicine, Oncology, Pharmacology +13

Structure‐Based Design of Selective Noncovalent CDK12 Inhibitors

Jeffrey W. Johannes, Christopher R. Denz, Nancy Su et al. · ChemMedChem · 2017 · 52 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13